Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.44 |
| ▸ | PDE4A | P27815 | 10/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924639 | 0.96 | PDE4D (0.45) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL2925826 | 0.92 | MAPT (0.42) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL2930395 | 0.92 | MAPT (0.42) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL2929410 | 0.90 | PDE4D (0.40) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL2927645 | 0.89 | PDE4B (0.48) | PDE4BPDE4AMAPTKMT2ALMNA | |
| SCHEMBL2928952 | 0.88 | PDE4D (0.39) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL2929288 | 0.86 | PDE4D (0.42) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL2932000 | 0.85 | PDE4D (0.54) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL2932654 | 0.85 | PDE4D (0.54) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL2929450 | 0.84 | MAPT (0.46) | PDE4BPDE4DPDE4APDE4CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | claimed |
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | SCHUMACHER RICHARD A | 2010-07-08 | — | — | US | claimed |
| US-7700631-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-20 | — | — | US | claimed |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | claimed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| EP-1569908-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | claimed |
| WO-2004046113-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | SCHUMACHER RICHARD A | 2010-07-08 | — | — | US | disclosed |
| US-7700631-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | disclosed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4D 6/4885PDE4A 1/4885 |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4D 5/4885PDE4A 1/4885 |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4D 6/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.